News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
<Research>JPM: Standardization of Service Pricing for CN Surgical Robots Conducive to MEDBOT-B Commercialization Prospects
China's National Healthcare Security Administration released on January 20 the Guidelines for the Establishment of Pricing Projects for Pathological Medical Services (Trial) an...
Reset
Send
The window will close in 5 seconds
<Research>JPM: Standardization of Service Pricing for CN Surgical Robots Conducive to MEDBOT-B Commercialization Prospects
Close
Recommend
8
Positive
10
Negative
7
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

China's National Healthcare Security Administration released on January 20 the Guidelines for the Establishment of Pricing Projects for Pathological Medical Services (Trial) and held a press briefing in Beijing, according to JPMorgan's report.

JPMorgan believes these guidelines will have a structurally positive impact on the Chinese surgical robot market, since they will establish a consistent pricing path while promoting the industry's transition towards a value-oriented and tiered reimbursement model.

The report highlighted MEDBOT-B (02252.HK)  -0.420 (-1.657%)    Short selling $11.14M; Ratio 17.482%   's rally of about 15% on the day of the announcement amid the market's highly positive response, reflecting improved visibility of the company's reimbursement mechanism and a clearer commercialization path.

JPMorgan has given MEDBOT-B an Overweight rating and a target price of HKD42.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-06-01 16:25.)

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.